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CD271 on Melanoma Cell Is an IFN-c-Inducible
Immunosuppressive Factor that Mediates
Downregulation of Melanoma Antigens
Junpei Furuta1, Takashi Inozume1, Kazutoshi Harada1 and Shinji Shimada1
IFN-g released from cytotoxic T lymphocytes (CTLs) during the effector phase is essential for rejecting bulky
melanoma tumors. In contrast, IFN-g is known to induce certain immunosuppressive factors in tumor cells such
as programmed cell death 1 ligand 1 (PD-L1). In this study, we have identified candidates for IFN-g-inducible
CTL-suppressive factors in melanoma cells using complementary DNA microarray analysis, and CD271/p75/
neurotrophin receptor (NTR) was one of the candidate genes. Recently, CD271 was identified as a marker of the
cancer stem cell–like population in human melanoma tissues. In this study, we showed that overexpression of
CD271 on melanoma cells suppressed the in vitro activation of melanoma-specific CTLs. This suppression was
mediated by CD271 ligation with activated CTL-derived nerve growth factor and the subsequent downregulation
of melanoma antigens. Moreover, we found that the expression levels of PD-L1 on melanoma cells correlated
with those of CD271, and they additively suppressed the activation of melanoma-specific CTLs. To the best of our
knowledge, the role of overexpression of CD271 in an anti-melanoma T-cell response has been unreported.
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INTRODUCTION
IFN-g, released from cytotoxic T lymphocytes (CTLs), is
indispensable for rejecting the bulky melanoma tumor
(Dudley et al., 2002; Palmer et al., 2008). However, IFN-g is
also known to induce immunosuppressive factors in melanoma
cells. Programmed cell death 1 ligand 1 (PD-L1/CD274/B7-H1)
is one of the important immunosuppressive factors (Dong et al.,
2002). PD-L1 can transduce a strong inhibitory signal into T
cells via interaction with programmed cell death 1 (PD-1/
CD279) that is expressed by either activated or exhausted T
cells (Keir et al., 2008). Melanoma-specific CTLs that infiltrate
the tumor largely express PD-1 (Ahmadzadeh et al., 2009;
Inozume et al., 2010) and are suppressed by PD-L1 expressed
on the melanoma cells (Inozume et al., 2010). Moreover, the
blockade for PD-L1/PD-1 interaction can enhance
antimelanoma immune responses in patients with melanoma
(Brahmer et al., 2012; Topalian et al., 2012). These findings
imply that the blockade for such IFN-g-inducible immuno-
suppressive factors is an effective strategy for treating patients
with melanoma in progressive stages.
In this report, we have identified CD271/p75/neurotrophin
receptor (NTR) as an IFN-g-induced CTL-suppressive factor.
Activated CTLs can release not only IFN-g but also b-nerve
growth factor (b-NGF), a ligand for CD271 that enhances the
CD271 signal in melanoma cells. This activated CD271 signal
can induce the subsequent downregulation of melanoma
antigens and eventually suppress CTL activation. Moreover,
we found that melanoma cells that express PD-L1 also express
CD271 after IFN-g stimulation, and both PD-L1 and CD271
additively suppress the activation of tumor-specific CTLs. Our
findings show a bidirectional intervention between CTLs and
melanoma cells. In addition, our observations imply that the
CD271 signal in melanoma cells should be inhibited to
enhance the antimelanoma immune response.
RESULTS
Activation of melanoma-specific CTLs by tumor stimulation was
attenuated when tumor cells were pretreated with IFN-c
To confirm the induction of IFN-g-inducible T cell–
suppressive factors in melanoma cells, we examined the
reactivity of HLA-A*0201-restricted MART-1 (melanoma-asso-
ciated antigen recognized by T cells 1)–specific CTLs against
melanoma cells with or without recombinant human IFN-g
(rhIFN-g) pretreatment. In 8/10 melanoma cell lines, CTL
suppression by pretreatment with rhIFN-g was observed in a
dose-dependent manner (representative data, 526mel and
1833mel are shown); this suppression was not observed in
two other cell lines (501Amel and 2487mel; Figure 1a and
Supplementary Figure S1 online). We also confirmed that
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Figure 1. Most melanoma cell lines became less sensitive to cytotoxic T lymphocyte (CTL) recognition when they were treated with IFN-c before exposure
to tumor-reactive CTLs, and blockade for programmed cell death 1 ligand 1 (PD-L1) was not sufficient to restore the suppression. (a) Melanoma cell lines
were treated with recombinant human IFN-g (rhIFN-g; at indicated concentrations) for 48 hours, and then washed and cocultured with MART-1 (melanoma-
associated antigen recognized by T cells 1)–specific CTLs. The activation of CTLs on melanoma cells was assessed by IFN-g release in culture supernatants
after its stimulation. These experiments were repeated three times, and representative examples are shown. (b, top panel) Melanoma cells transduced with the
PD-L1 gene were cocultured with MART-1-specific CTLs in the presence or absence of the anti-PD-L1-blocking antibody. (b, bottom panel) Melanoma
cell lines were treated with rhIFN-g for 48 hours, and then washed and cocultured with MART-1-specific CTLs in the presence or absence of anti-PD-L1-blocking
antibody. Histograms show PD-L1 expression on the stimulator cells. The line indicates isotype control; gray shading indicates staining for PD-L1.
These experiments were repeated three times, and representative examples are shown. NS, not significant; NT, non treated.
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501Amel did not have a defect in IFN-g signaling
(Supplementary Figure S1 online). Because PD-L1 is known
as an important T cell–suppressive factor in melanoma cells
that is induced by IFN-g (Dong et al., 2002), we assessed the
contribution of PD-L1/PD-1 interaction in this CTL
suppression (Figure 1b). The upper panel shows the blocking
effect of the anti-PD-L1 antibody used in the experiment. The
suppressive effect of retrovirally transduced PD-L1 was almost
completely restored by the addition of the antibody. However,
the same amount of anti-PD-L1-blocking antibody was not
sufficient to restore the suppression induced by pretreatment
with rhIFN-g (Figure 1b, bottom). These data suggest that there
may be additional IFN-g-inducible, T cell–suppressive
mechanisms other than PD-L1.
Upregulation of CD271 on 526mel and 1833mel by IFN-c
stimulation
To identify the IFN-g-inducible genes involved in CTL sup-
pression in Figure 1, we compared the gene expression
profiles between the ‘‘IFN-g-resistant’’ cell lines (501Amel
and 2487mel) and the ‘‘IFN-g-susceptible’’ cell lines (526mel
and 1833mel). First, we selected genes that were upregulated
by 45fold in the 526mel and 1833mel lines by rhIFN-g
treatment and did not increase in 2487mel and 501Amel
(Table 1). The 74 candidate genes were selected using these
criteria. The representative IFN-g-inducible T cell–suppressive
gene, PD-L1, was included in this group. In these candidate
genes, we focused on CD271/p75/NTR because recently this
molecule was reported as being crucial in identifying the
tumor-initiating populations in melanoma tissues; these popu-
lations exist in most melanoma tissues in various frequencies
(Boiko et al., 2010). In addition, a recent report showed that
CD271 was upregulated on melanoma cells by IFN-g and
tumor necrosis factor-a (TNF-a) stimulation (Landsberg et al.,
2012). We could confirm that CD271 was clearly upregulated
by stimulation with rhIFN-g and recombinant human TNF-a in
526mel, 1833mel, and most of the other melanoma cells that
we tested. However, CD271 was not upregulated in 2487mel
and 501Amel (Figure 2).
Overexpression of CD271 on melanoma cells suppressed the
activation of melanoma-specific CTLs
b-NGF, a ligand for CD271, is produced from various kinds of
cells and is reported to activate the CD271 signal in nerve
cells and breast cancer cells (Micera et al., 2007). To examine
the effect of overexpression of CD271 on CTL activation, we
completed the coculture assay using MART-1-specific CTLs
and 501Amel cells with or without CD271 gene transduction.
The 501mel does not endogenously express CD271 (Figures 2
and 3b). Before the assay, we could confirm the production of
b-NGF from CTLs and the transgene expression in 501Amel
(Figure 3a and b). A previous report showed that the high
population of CD271 in melanoma tissues expresses fewer
melanoma antigens (Boiko et al., 2010). Therefore, we
compared the expression levels of the MART-1 antigen
among the transfectants (Figure 3c, left). In addition,
1833mel was sorted into CD271-high and CD271-low popu-
lations, and the expression level of MART-1 was compared
Table 1. Genes upregulated in 526mel and 1833mel by
stimulation with IFN-g
Gene symbol UniGene ID
ASS1 Hs.160786
SSTR2 Hs.514451
PARP12 Hs.12646
HLA-DPB1 Hs.485130
OASL Hs.118633
C10orf81 Hs.228320
SPTA1 Hs.119825
HLA-DQA2 Hs.591798
CSF1 Hs.591402
LPHN3 Hs.570770
ABCF2 Hs.654958
HLA-DRB1 Hs.696211
SCN4A Hs.46038
TNFRSF1B Hs.256278
UBA7 Hs.16695
C1S Hs.458355
PRDM16 Hs.99500
BMP6 Hs.285671
PAFAH2 Hs.477083
IFI35 Hs.632258
BST2 Hs.118110
IRF8 Hs.137427
PSMB8 Hs.180062
CSRP1 Hs.108080
WASF2 Hs.590909
ANKRD29 Hs.374774
HLA-DRB4 Hs.696211
CIDEC Hs.567562
APOBEC3G Hs.660143
LCAT Hs.387239
FAM167A Hs.124299
FOSL1 Hs.283565
IL10RB Hs.654593
SERPING1 Hs.384598
HLA-DMA Hs.351279
SOCS3 Hs.527973
HLA-DMA Hs.351279
TNFSF13B Hs.525157
PVR Hs.171844
CD74 Hs.436568
HLA-F Hs.519972
NRP1 Hs.131704
IFIT3 Hs.714337
IFNAR2 Hs.708195
NGFR (CD271) Hs.415768
Table 1 continued on following page
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between the two populations (Figure 3c, right). In both cases,
the expression levels of CD271 itself did not affect the
expression level of MART-1. In addition, expression levels of
HLA-A*0201 were not altered (Supplementary Figure S3
online). However, activation of CTLs in the 48 hour coculture
assay was significantly suppressed by the overexpression of
CD271 on melanoma cells (Figure 3d). To examine whether
the ligation of CD271 on the melanoma cells by b-NGF had
any role in CTL suppression, we performed the coculture assay
in the presence of an anti-NGF antibody; we confirmed that
the addition of the anti-NGF antibody reversed CTL suppres-
sion (Figure 3e, left). Moreover, pretreatment of 501Amel
CD271 cells by the exogenous b-NGF resulted in the
attenuation of tumor recognition by CTLs, even in the short-
term (3 hours) cell-killing assay (Figure 3e, right). The suppres-
sive effect of CD271 was reversed by truncation of the
intracellular domain (Supplementary Figure S2a online), and
the culture supernatant derived from 501mel-CD271 cells
stimulated with b-NGF did not suppress the CTL activation
(Supplementary Figure S2b online). These data suggest that
suppression of the CTL function by melanoma cells expressing
CD271 was intrinsic to the melanoma cells.
Enhanced CD271 signal in melanoma cells induced NF-jB
activation and subsequent downregulation of melanoma antigens
Some previous reports have shown that the CD271 signal
activates a transcription factor, NF-kB (Micera et al., 2007). To
examine the mechanism of CTL suppression through an
enhanced CD271 signal in melanoma cells, we compared
the state of NF-kB among the transfectants. To provide enough
b-NGF in the absence of activated CTLs, the transfectants were
stimulated with exogenous b-NGF. In the 501Amel CD271
cells, enhanced and decreased nuclear translocation of
NF-kB and microphthalmia-associated transcription factor,
respectively, was detected (Figure 4a). Furthermore, we exam-
ined whether the CD271 ligation by b-NGF altered the amount
of melanoma antigens (Figure 4b); we found that the amounts
of MART-1 and gp100 antigens decreased by stimulation with
exogenous b-NGF. In fact, enhanced CD271 signal in mela-
noma cells attenuated the signal of the MART-1-specific TCR
(Supplementary Figure S2c online), and CTL suppression was
rescued by addition of the synthetic MART-1 peptide
(Supplementary Figure S2d online). These results imply that
the attenuation of tumor recognition by CTLs was caused by
enhancement of the CD271 signal and by subsequent down-
regulation of melanoma antigens in the melanoma cells.
PD-L1 and CD271 additively suppress the activation of
MART-1-specific CTLs
PD-L1 is a representative T cell–suppressive molecule that is
induced on melanoma cells by IFN-g. We examined the
relationship between the expression levels of PD-L1 and
CD271 on melanoma cells after rhIFN-g stimulation and found
that the melanoma cells that expressed high levels of PD-L1
also expressed CD271 (Figure 5a). Such a trend was also
observed in our immunohistochemical analysis (Supplemen-
tary Figure S4 online). Furthermore, we examined whether
CD271 and PD-L1 synergistically suppressed CTL activation
(Figure 5b). In the coculture assay, overexpression of PD-L1
and CD271 independently suppressed CTL activation, and an
additive effect was also observed. We could confirm that the
CD271 signal in melanoma cells did not alter the expression
levels of PD-L1 and HLA-A*0201 on melanoma cells
(Supplementary Figure S3 online). Taken together, CD271
and PD-L1 seemed to suppress the CTLs independently.
DISCUSSION
IFN-g is a ‘‘double-edged sword’’ that has antitumor (Palmer
et al., 2008) and protumor (Zaidi and Merlino, 2011) effects.
PD-L1 is a representative IFN-g-inducible T cell–suppressive
molecule (Dong et al., 2002), and there is a correlation
between the prognosis of patients with melanoma and the
expression levels of PD-L1 in melanoma tissues (Hino et al.,
2010). Our data (Figure 1b) suggest the existence of other IFN-
g-inducible T cell–suppressive genes. Therefore, we attempted
Table 1. (Continued )
Gene symbol UniGene ID
LOC100132288 Hs.487562
HLA-DMB Hs.654428
AIM2 Hs.281898
HLA-DQA1 Hs.387679
SRF Hs.520140
HLA-DPA1 Hs.347270
NCRNA00171 Hs.653168
MRPL17 Hs.523456
HLA-DPA1 Hs.347270
C6orf81 Hs.533066
LIN52 Hs.612866
HLA-DPB1 Hs.485130
TNFRSF12A Hs.355899
ANKRD19 Hs.643597
HLA-DRB5 Hs.534322
HLA-DQA1 Hs.387679
KALRN Hs.8004
NOP56 Hs.376064
MYOF Hs.602086
PDL1(CD274) Hs.521989
BET1L Hs.414418
C2orf18 Hs.516034
LOC400759 Hs.661968
LOC220429 Hs.623891
LOC284080 Hs.274864
FAM167A Hs.124299
FAM188B Hs.660192
TEKT4 Hs.631517
BDNF Hs.502182
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to identify any IFN-g-inducible T cell–suppressive molecules
other than PD-L1 by comparing the gene expression profiles
between ‘‘IFN-g-susceptible melanoma cells’’ (526mel and
1833mel) and ‘‘IFN-g-resistant melanoma cells’’ (501Amel
and 2487mel; Figure 1a). There was a possibility that
differences between ‘‘IFN-g-susceptible melanoma cells’’
and ‘‘IFN-g-resistant melanoma cells’’ were caused by a defect
in IFN-g signaling. However, we have shown that HLA-DR
was upregulated on 501Amel (‘‘IFN-g-resistant’’ cell line) by
IFN-g simulation. Therefore, 501Amel seemed not to have an
early defect in IFN-g signaling (Supplementary Figure S1
online). Identification of T cell–suppressive factors and gen-
eration of methods to remove their suppressive effects will be
necessary to elicit an antimelanoma immune response, similar
to that with the anti-PD-1 or anti-PD-L1 antibody (Brahmer
et al., 2012; Topalian et al., 2012).
CD271 is a low-affinity NTR that can bind to neurotrophins
including b-NGF (Micera et al., 2007). This molecule is
currently reported as a marker of a tumorigenic, tumor stem
cell–like population (Boiko et al., 2010), and also as a marker
of inflammation-induced ‘‘dedifferentiated’’ cells in
melanoma tissues (Landsberg et al., 2012). In these reports,
the authors showed that the expression level of CD271 on
melanoma cells is upregulated by stimulation with TNF-a and
IFN-g. Similarly, in our experiment, the expression level of
CD271 was markedly upregulated in melanoma cells by IFN-g
stimulation (Figure 2). In addition, we could detect the
production of b-NGF in MART-1-specific CTLs upon encoun-
tering melanoma cells (Figure 3a). Therefore, we hypothesized
that the CD271 signal in melanoma cells may have a role in
CTL suppression (Figure 1). Moreover, we could detect that
CTL activation was significantly suppressed by the overexpres-
sion of CD271 on melanoma cells in an in vitro coculture
assay (Figure 3d), and CTL suppression was reversed by the
addition of the anti-NGF antibody (Figure 3e). There are
several possible mechanisms for CTL suppression. We have
shown that CD271 lacking the intracytoplasmic signaling
domain did not suppress the CTLs (Supplementary Figure
S2a online). This suggested that the suppression was not
mediated by direct interaction between CD271 on melanoma
IFN-γ
(1,000 IU ml–1, 48 hours)–
TNF-α
(1,000 IU ml–1, 48 hours)
2487mel
526mel
1833mel
501Amel
Figure 2. Upregulation of CD271 on 526mel and 1833mel by stimulation with IFN-c and tumor necrosis factor-a (TNF-a). Melanoma cells were cultured
in the presence or absence of recombinant human (rh)IFN-g or rhTNF-a (1,000 U ml1, 48 hours), and then washed and stained with anti-human CD271 antibody.
The line indicates isotype control; gray shading indicates staining for CD271.
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Figure 3. Overexpression of CD271 on melanoma cells suppresses the activation of melanoma-specific cytotoxic T lymphocytes (CTLs) via ligation with
nerve growth factor (NGF). (a) Activated T cells can produce NGF. MART-1 (melanoma-associated antigen recognized by T cells 1)–specific CTLs were stimulated
with phorbol 12-myristate 13-acetate (PMA)/ionomycin or melanoma cells expressing HLA-A*0201 and MART-1 antigen in the presence of brefeldin A.
Intracellular expression of pro-NGF was detected by western blot analysis using cell lysates. (b) Expression of CD271 in the transfectants. 501Amel transfected
with Mock or CD271 gene (501Amel-CD271) was stained with anti-CD271 antibody. The line indicates isotype control; gray shading indicates staining for
CD271. (c) Overexpression of CD271 on melanoma cells itself did not alter the expression level of MART-1 antigen. The mRNA expression levels of MART-1 were
compared between 501Amel transduced with mock and 501Amel transduced with CD271 by quantitative PCR (left panel). The expression level of MART-1
protein was compared between FACS-sorted CD271-high and CD271-low populations of 1833mel by western blot analysis (right panel). (d) Overexpression
of CD271 on melanoma cells suppresses the activation of melanoma-reactive CTLs. MART-1-specific CTLs were cocultured with 501Amel transduced with mock
and 501Amel transduced with CD271. The activation of CTLs was assessed by cytokine release from T cells in culture supernatants. These experiments were
repeated three times, and representative examples are shown. (e) CTL suppression was mediated by CD271 ligation with NGF. Melanoma cell lines were
cocultured with MART-1-specific CTLs in the presence of the anti-NGF antibody. The activation of CTLs was assessed by cytokine release from T cells in culture
supernatants (left panel). Melanoma cell lines were treated with recombinant b-NGF (500 ng ml1, for the indicated amount of time), and then washed and
cocultured with MART-1-specific CTLs for 3 hours. The killing of melanoma cells by CTLs was assessed by calcein release in culture supernatants (right panel).
These experiments were repeated three times, and representative examples are shown.
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cells and some receptors on T cells. Furthermore, culture
supernatant derived from 501mel-CD271 cells stimulated with
b-NGF did not suppress the CTL activation (Supplementary
Figure S2b online), and the suppressive effect was mediated by
attenuating the TCR signal (Supplementary Figure S2c online).
These data indicated that suppression of T-cell effector
function by melanoma cells expressing CD271 may be
intrinsic to melanoma cells. Previous reports have also shown
TNF-a stimulation–induced upregulation of CD271 and loss of
differentiation antigens (MART-1 and gp100) in melanoma
cells (Boiko et al., 2010; Landsberg et al., 2012). However, in
these reports, the function of CD271 on these melanoma cells
was not examined. In our experiment, the expression level of
MART-1 was not altered by the overexpression of CD271 itself
(Figure 3c); however, it was decreased by ligation with b-NGF
(Figure 4b). Taken together, upregulation of CD271 on
melanoma cells by IFN-g seems to be a functional receptor
that mediates CTL suppression. To the best of our knowledge,
our results showing the function of CD271 on melanoma cells
are previously unreported.
PD-L1 is one of the important T cell–suppressive molecules
induced by IFN-g stimulation on melanoma cells. Our data in
Figure 1b suggest that T-cell suppression in Figure 1a was
mediated not only by PD-L1 but also by other IFN-g-inducible
T cell–suppressive factors. We examined whether the over-
expression of PD-L1 and CD271 on melanoma cells can
synergistically or additively suppress CTL activation and found
the additive effect of the PD-L1 and CD271 signal. Moreover,
we found that PD-L1-expressing melanoma cells tend to
express CD271 (Figure 5b). These findings suggest that the
inhibition of the CD271 signal in melanoma cells may be
useful to enhance the antitumor effect of anti-PD-1 or anti-PD-
L1-blocking antibodies.
In this report, we identified CD271 as an IFN-g-inducible, T
cell–suppressive molecule on melanoma cells. To the best of
our knowledge, the function of CD271 on melanoma cells has
not been reported previously. In addition, our observation
suggests that identification and characterization of IFN-g-
inducible T cell–suppressive molecules other than PD-L1
may be important for the development of more effective
antimelanoma immunotherapies.
MATERIALS AND METHODS
Cell lines
All melanoma cell lines used in this study were established at Surgery
Branch, National Cancer Institute, National Institutes of Health
(Bethesda, MD). The 293GP cells were purchased from ATCC
(Manassas, VA).
GeneChip analysis
Double-stranded complementary DNAs were synthesized from
mRNAs extracted from melanoma cell lines that express MART-1
0 h
ou
rs
6 h
ou
rs
12
 ho
urs
24
 ho
urs
48
 ho
urs
501Amel-CD271501Amel-Mock
β-NGF 0.5 μg ml–1
gp100
MART-1
Actin
0 h
ou
rs
6 h
ou
rs
12
 ho
urs
24
 ho
urs
48
 ho
urs
MITF
501Amel-CD271501Amel-Mock
0 30 120 min 0 30 120 minβ-NGF 0.5 μg ml–1
MITF
NFκβ
Lamin A/C
a
b
Figure 4. Cytotoxic T lymphocyte (CTL) suppression is mediated by enhanced
CD271 signal in melanoma cells via subsequent downregulation of melanoma
antigens. (a) CD271 ligation with b-nerve growth factor (b-NGF) induces the
nuclear translocation of NF-kB and reduces the nuclear translocation of
microphthalmia-associated transcription factor (MITF). The transfectants were
treated with recombinant human b-NGF, and then the nuclear extracts were
purified and the amounts of NF-kB and MITF in nuclei were quantified by
western blot analysis. These experiments were repeated three times, and
representative examples are shown. (b) Expression levels of MITF, MART-1
(melanoma-associated antigen recognized by T cells 1), and gp100 were
examined by western blot analysis using whole-cell lysates of the transfectants
that were pretreated with recombinant human b-NGF. These experiments were
repeated three times, and representative examples are shown.
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Figure 5. CD271 and programmed cell death 1 ligand 1 (PD-L1) additively
suppress the activation of melanoma-specific cytotoxic T lymphocytes (CTLs).
(a) Expression levels of CD271 on melanoma cells correlate with those of PD-
L1. Melanoma cells were treated with rhIFN-g (1,000 U ml1, 48 hours), and
then stained with anti-CD271 and anti-PD-L1 antibodies. The line indicates
isotype control; gray shading indicates staining for CD271. The correlations of
mean fluorescence intensities (MFIs) were analyzed. (b) PD-L1 and CD271
signal additively suppress the activation of melanoma-specific CTLs. MART-1
(melanoma-associated antigen recognized by T cells 1)–specific CTLs were
cocultured with 501Amel transduced with CD271, PD-L1, or both. Activation
of CTLs was assessed by cytokine released from T cells in culture supernatants.
These experiments were repeated three times, and representative examples are
shown.
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and HLA-A*0201 (526mel, 1833mel, 2487mel, and 501Amel), with
or without pretreatment with rhIFN-g (1,000 U ml 1, 48 hours). The
GeneChip analysis was performed according to the manufacturer’s
instructions (HumanG3 60K, Agilent, Tokyo, Japan). After rhIFN-g
stimulation, genes that increased by 45-fold in 526mel and 1833mel
and did not increase in 2487mel and 501Amel were selected as
candidates for analysis. The data have been deposited at the Gene
Expression Omnibus repository (GSE51259).
Generation of cell lines that stably express human CD271 and
PD-L1
Human melanoma cell lines (established in the Surgery Branch,
National Cancer Institute, as previously described) were cultured in
RPMI-1640 (Grand Island, NY) supplemented with 10% fetal bovine
serum and antibiotics. To introduce genes into the cell lines, the
human CD271 gene was cloned by reverse transcription–PCR from
the human melanoma cell line 526mel. The gene was sequenced and
subcloned into the retroviral vector pQCXIP (Clontech, Mountain
View, CA). The plasmid encoding human PD-L1 was a gift from
Dr Ken-ichi Hanada (Surgery Branch, National Cancer Institute).
Vesicular stomatitis virus G protein–pseudotyped retrovirus was pre-
pared by transiently transfecting the 293GP cell line, as previously
described by Wang et al. (2005). Melanoma tumor cell lines were then
infected with filtered cell-free viral supernatant in the presence of
8mg ml 1 polybrene and subsequently maintained in selection medium
with 10mg ml 1 puromycin (Sigma-Aldrich Japan, Tokyo, Japan).
Retroviral transduction of peripheral blood lymphocytes
The plasmid encoding MART-1-specific TCR was also a gift from Dr
Ken-ichi Hanada (Johnson et al., 2009). Peripheral blood lymphocytes
from healthy donors were stimulated with soluble OKT-3 (50 ng ml 1;
eBioscience, San Diego, CA) and recombinant human IL-2
(300 IU ml 1) for 2 days before transduction was performed. The
stimulated cells were added to 24-well plates, initially coated with
RetroNectin (10mg per well in 400ml of phosphate-buffered saline;
Takara Shuzo, Kyoto, Japan), and subsequently precoated with
retrovirus by spinoculation (2,000g, 32 1C, 2 hours). The plates were
then centrifuged at 1,000g for 10 minutes and incubated overnight at
37 1C in a 5% CO2 incubator. This procedure was repeated the next
day, and the cells were split as required to maintain a cell density of
between 0.5 and 1 106 cells per ml.
Antibodies and reagents
Recombinant human IFN-g, TNF-a, and b-NGF were purchased from
R&D Systems (Minneapolis, MN). The following mAb, which are
specific for human antigens, were purchased from BD Bioscience
(San Jose, CA): phycoerythrin (PE)-conjugated anti-human CD271
(C40-1457), PE-conjugated anti-human PD-L1 (MIH1), and isotype
controls conjugated to PE. The purified anti-b-NGF antibody, anti-NF-
kB antibody, anti-lamin A/C antibody, and horseradish peroxidase–
conjugated antibodies that were used in the western blot were all
purchased from Cell Signaling (Danvers, MA). The anti-MART-1
antibody that was also used in the western blot was purchased from
Sigma-Aldrich. The anti-gp100 and anti-microphthalmia-associated
transcription factor antibodies used in the western blot were pur-
chased from Abcam (Tokyo, Japan). The anti-NGF and isotype control
antibodies used in the coculture assay were purchased from Biole-
gend (San Diego, CA) and the sodium azide was removed by dialysis.
Western blot analysis
The cells were collected and then lysed. In some experiments, the cells
were stimulated with recombinant b-NGF (R&D Systems), and the
nuclear extracts were isolated using a nuclear and cytoplasm extraction
reagent (Thermo Scientific, Rockford, IL). The lysates (20mg) were
electrophoresed on a 4–12% Bis-Tris gel (Invitrogen, Tokyo, Japan) and
then transferred to a nitrocellulose membrane. After blocking the
membrane with 3% BSA in Tris-buffered saline, containing 0.1%
Tween-20, the membrane was incubated overnight with the primary
antibody and then washed three times with Tris-buffered saline
containing 0.1% Tween-20 (10 minutes each time). After incubation
with the horseradish peroxidase–conjugated secondary antibody (IgG)
for 1 hour, the membranes were washed four times. The signal was
then visualized with the SuperSignal West Dura Extended Duration
Substrate (Thermo Fisher Scientific, Yokohama, Japan).
Flow cytometry analysis
In some experiments, the cells were treated with rhIFN-g or
recombinant human TNF-a (1,000 U ml 1, 48 hours) and washed
before staining. The cell lines were resuspended in the staining buffer
(phosphate-buffered saline containing 3% fetal bovine serum) and
stained with fluorochrome-conjugated antibodies. The stained cells
were subsequently washed in the staining buffer twice and briefly
stained with propidium iodide to exclude nonviable cells before
analysis in a FACSCalibur flow cytometer (Becton Dickinson, San
Jose, CA). For FACS sorting, 1833mel was stained with PE-conjugated
anti-CD271 antibody for 1 hour. After washing, the cells were briefly
stained with propidium iodide to exclude nonviable cells. During the
cell sorting analysis, melanoma cells were divided into a CD271-high
propidium iodide population and a CD271-low propidium iodide
population by the FACSAria cell sorter (Becton Dickinson).
Real-time quantitative reverse transcription–PCR
The relative mRNA expression was determined by reverse
transcription–PCR using an ABI PRISM 5500 Sequence Detection
System (Applied Biosystems, Foster City, CA) with SYBR Green I dye
(QIAGEN, Valencia, CA), as previously described (Okamoto et al.,
2010). The primers used to detect the MART-1 gene and GAPDH3
gene were as follows: MART-1, forward 50-ATGCCAAGAGAAG
ATGCTCA-30 and reverse 50-AGCATGTCTCAGGTGTCTCG-30; GA
PDH3, forward 50-CCACCCATGGCAATTTCCATGGCA-30 and
reverse 50-TCTAGACGGCAGGTCAGGTCCACC-30.
Calcein release and cytokine assays
Calcein release assays using the melanoma-specific CTLs and the
transfectants were performed as previously described (Shibagaki and
Udey, 2002). The stimulators were pretreated with recombinant b-
NGF (500 ng ml 1) for the indicated amount of time, and then
washed and cocultured with CTLs for 3 hours. The effector-to-target
ratio was 10:1. In the cytokine release assays, the cultured tumor lines
(5–10 104 cells per well) were used as target cells. In some
experiments, cells were treated with rhIFN-g (1,000 U ml 1,
48 hours) and washed three times before coculture. In some
experiments, anti-NGF mAb (Biolegend), anti-PD-L1 mAb
(eBioscience), or isotype controls were added at 10mg ml 1.
Tumor-specific T cells at 104 cells per well were added to the
tumor cells to a final volume of 200ml and incubated for 48 hours.
The supernatant was assayed using ELISA for IFN-g (eBioscience).
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Statistical analysis
Student’s t-test was used to evaluate significant differences in
enumeration assays. The value of Po0.05 was considered statistically
significant.
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